


# Industry Programme





## Exhibition Area



### Directory

### Booth Code

|                              |          |
|------------------------------|----------|
| Aeon Astron Europe           | 20       |
| Aerie Pharmaceutical         | 19       |
| Alcon                        | 44+45+46 |
| Allergan                     | EP4      |
| Beaver-Visitec International | 57       |
| CenterVue                    | 54+55    |
| Diopsys                      | 35       |
| EBS Technologies             | 56       |
| Ellex                        | 50       |
| Eye Tech Care                | 29+30    |
| FB Vision                    | 53       |
| Glaukos Corporation          | EP2      |
| Haag-Streit Diagnostics      | 24       |
| Heidelberg Engineering       | 41+42    |
| Glaucomics                   | 12       |
| IOptima                      | 22       |
| Iridex                       | 18       |
| iSTAR Medical                | 10       |
| Molteno Ophthalmic           | 34       |
| NeoMedix Corporation         | 25       |
| New World Medical            | 38       |
| Nidek Co.                    | 21       |
| Novartis Farma               | 39+40    |
| Oculus Optikgeräte           | 37       |
| Omikron Italia               | 26+27+28 |
| Optovue                      | 58+59    |
| Quantel Medical              | 43       |
| Rheon Medical                | 36       |
| Santen                       | EP3      |
| Théa                         | 31+32+33 |
| VISUfarma                    | 47+48+49 |
| Wisepress Medical Bookshop   | 1+2+3    |
| World Glaucoma Association   | 11       |
| Zeiss Medical Technology     | 8+9      |

## Saturday, 19 May 2018

| 17.10 - 18.30  | Educational Partner Plenary Symposium - Santen   | Main Auditorium |
|----------------|--|-----------------|
|                | Decoding glaucoma: A place for 24-hour IOP control<br>Chair: <b>Carlo Enrico Traverso</b> (Italy)      |                 |
| 17.10<br>IS1.1 | Welcome and introduction<br><b>Carlo Enrico Traverso</b> (Italy)                                       |                 |
| 17.15<br>IS1.2 | The role of 24-hour IOP control in glaucoma management<br><b>Luciano Quaranta</b> (Italy)              |                 |
| 17.35<br>IS1.3 | Therapeutic approaches for maintaining 24-hour IOP control<br><b>Anastasios G.P. Konstas</b> (Greece)  |                 |
| 17.55<br>IS1.4 | Managing glaucoma in daily practice: An interactive case study<br><b>António Figueiredo</b> (Portugal) |                 |
| 18.20          | Q&A and closing remarks<br>Chair / All   |                 |

## Sunday, 20 May 2018

| 07.30 - 08.30  | Industry Parallel Symposium - Diopsys   | Room Donatello |
|----------------|---|----------------|
|                | Modern electrophysiology for early diagnosis and management of glaucoma                                       |                |
| 07.30<br>IS2.1 | Early diagnosis and management of glaucoma using modern electrophysiology and SLT<br><b>Mark Latina</b> (USA) |                |
| 07.55<br>IS2.2 | Using modern ERG in diagnosis and management of glaucoma<br><b>André Mermoud</b> (Switzerland)                |                |
| 08.20          | Discussion  |                |



Sunday, 20 May 2018

07.30 - 08.30

**Industry Parallel Symposium - Iridex**

**Room Brunelleschi**

**MicroPulse therapy: a choice before, in combination with, and after any other glaucoma treatment**

7.30

IS3.1

Introduction to MicroPulse technology, clinical summary and treatment technique  
**Ziad Khoueir** (Lebanon)

07.45

IS3.2

MicroPulse TS CPC in Netherlands; clinical experience and various patient's profiles  
**Ronald M.P.C. de Crom** (Netherlands)

08.00

IS3.3

MicroPulse CPC treatment in University of Zurich and my patient's profiles  
**Marc Töteberg-Harms** (Switzerland)

08.15

IS3.4

Questions and Answers  
**Karin Roswitha Pillunat** (Germany)

12.00 - 13.30

**Educational Partner Plenary Symposium - Glaukos**

**Main Auditorium**

**Transforming glaucoma therapy**  
Chairman: **Rick Lewis** (USA)

12.00

IS4.1

Introduction  
**Rick Lewis** (USA)

12.05

IS4.2

The MIGS treatment algorithm  
**Carl Erb** (Germany)

12.20

Discussion / Questions & answers

12.25

IS4.3

Best practices with multiple trabecular meshwork stents  
**Florian Rüfer** (Germany)

12.40

Discussion / Questions & answers

12.45

IS4.4

Long-term MIGS data review  
**Rick Lewis** (USA)

13.00

Discussion / Questions & answers

13.05

IS4.5

New sustained-release drug delivery implant - overview of technology, implantation technique, recent data  
**Gus Gazzard** (United Kingdom)

13.20

Discussion / Questions & answers

13.25

IS4.6

Final comments and close  
**Rick Lewis** (USA)

Sunday, 20 May 2018

**16.30 - 17.30 Industry Parallel Symposium - Novartis Room Michelangelo**

**Maximal medical therapy: why, how and who**  
Chairman: **Carlo Enrico Traverso** (Italy)

**16.30**  
**IS5.1** Why is still a worth talking about?  
**Carlo Enrico Traverso** (Italy)

**16.45**  
**IS5.2** How to get it?  
**Stefano Gandolfi** (Italy)

**17.00**  
**IS5.3** Who is the candidate for MMT?  
**Luca Rossetti** (Italy)

**17.15**  
Discussion and take home messages  
**All**

**16.30 - 17.30 Industry Parallel Symposium - Théa Room Leonardo**

**Modern management of glaucoma: an update**  
Chairman: **Keith Barton** (United Kingdom)

**16.30**  
**IS6.1** The same, but different: managing glaucoma across the EU  
**Miriam Kolko** (Denmark)

**16.42**  
**IS6.2** Challenges in glaucoma assessment in the clinic  
**Luis Abegão Pinto** (Portugal)

**16.54**  
**IS6.3** Is any glaucoma treatment kind to the ocular surface?  
**Anton Hommer** (Austria)

**17.06**  
**IS6.4** MIGS: where are we now, where are we going?  
**Keith Barton** (United Kingdom)

**17.18**  
**IS6.5** The future of glaucoma therapy  
**Gus Gazzard** (United Kingdom)



Sunday, 20 May 2018

**16.30 - 17.30 Industry Parallel Symposium - Omikron Italia Room Giotto**

**Neuroprotection and Neuroenhancement: from the clinical evidences to the improvement of Quality of Life in glaucomatous patients**  
Chairmen: **Francisco Javier Goñi** (Spain), **Fotis Topouzis** (Greece)

**16.30** Successes and limitations of glaucoma therapy  
**IS7.1** **Fotis Topouzis** (Greece)

**16.45** Neuroprotection in glaucoma  
**IS7.2** **Stefano Gandolfi** (Italy)

**16.55** Clinical evidences of neuroprotection and neuroenhancement in glaucoma  
**IS7.3** **Luca Rossetti** (Italy)

**17.10** Is it possible to think about topical neuroprotection?  
**IS7.4** **Gianluca Manni** (Italy)

**17.20** Rational and RCT on Quality of Life in glaucoma  
**IS7.5** **Francisco Javier Goñi** (Spain)

*You will be pleased with a Welcome Coffee*

**16.30 - 17.30 Industry Parallel Symposium - Ellex Room Cimabue**

**SLT and MIGS - And the glaucoma treatment paradigm**  
Chairman: **David Lubeck** (USA)

**16.30** Introduction

**16.35** SLT in the era of MIGS  
**IS8.1** **Myrjam De Keyser** (Belgium)

**16.50** ABiC in the MIGS treatment armamentarium  
**IS8.2** **David Lubeck** (USA)

**17.05** ABiC: finding the right patient  
**IS8.3** **Fiamma Campana** (Italy)

**17.20** Questions & answers

Sunday, 20 May 2018

**17.00 - 18.00 Industry Parallel Symposium - Quantel Medical Room Botticelli****Glaucoma diagnosis and treatment: current practice and new directions**Chairman: **Mark Latina** (USA)**17.00** Clinical interest of UBM in the diagnosis and management of glaucoma  
**IS9.1** **Filippo Romanazzi** (Italy)**17.15** Early diagnosis of glaucoma with pattern ERG  
**IS9.2** **Mark Latina** (USA)**17.30** How to best use SLT in your practice?  
**IS9.3** **Mark Latina** (USA)**17.45** Subcyclo: a new perspective in glaucoma treatment  
**IS9.4** **Yves Lachkar** (France)**16.30 - 17.30 Industry Parallel Symposium - Heidelberg Engineering Room Donatello****The Glaucoma cookbook!**Chairman: **Stephan Schulz** (Germany)**16.30** Glaucoma ingredients - ONH and macula anatomic structures  
**IS10.1** **Jost Jonas** (Germany)**16.45** Glaucoma recipes - From lamina to ganglion cells  
**IS10.2** **Francesco Oddone** (Italy)**17.00** Glaucoma cooking - Spicy data combination: cases  
**IS10.3** **Marta Pazos** (Spain)**17.10** Glaucoma cooking - too spicy: recognizing artifacts  
**IS10.4** **Hans Lemij** (Netherlands)**17.20** Discussion



**Sunday, 20 May 2018**

**16.30 - 18.00 Industry Parallel Symposium - Alcon Room Brunelleschi**

**The supraciliary micro-stent - A breakthrough option for the treatment of glaucoma: a clinical case study discussion**

Chairman: **Leon Au** (United Kingdom)

**16.30** The role for MIGS and the supraciliary space in the treatment of glaucoma  
**IS11.1** **Leon Au** (United Kingdom)

**16.40** Innovation in MIGS Technology using the supraciliary space  
**IS11.2** **Esther Hoffman** (Germany)

**16.50** Key clinical data and surgeon experience with the supraciliary micro-stent  
**IS11.3** **Alfonso Anton Lopez** (Spain), **Marc Töteberg-Harms** (Switzerland),  
**Helmut Höh** (Germany), **Steven Vold** (USA)

**17.35** The supraciliary micro-stent: patient profiles  
**IS11.4** **Leon Au** (United Kingdom)

**17.45** Questions & answers  
**IS11.5** **Leon Au** (United Kingdom)

**16.30 - 17.30 Industry Parallel Symposium - Eye Tech Care Room Vasari**

**Focused Ultrasound: update on European clinical studies and practical implications**

Chairman: **Marco Nardi** (Italy)

**16.30** Latest research on UCP and ciliary body imaging  
**IS12.1** **Philippe Denis** (France)

**16.45** European study results: 1 year study follow-up  
**IS12.2** **Ingeborg Stalmans** (Belgium)

**17.00** Side effects: risk factors and how to manage? Results of a pupillometry study  
**IS12.3** **Luis Abegão Pinto** (Portugal)

**17.15** Multiple treatments: why, when and how to retreat?  
**IS12.4** **Simonetta Morselli** (Italy), **Alessandra De Gregorio** (Italy)



Monday, 21 May 2018

| 12.00 - 13.30                 | Educational Partner Plenary Symposium - Allergan  | Main Auditorium |
|-------------------------------|---|-----------------|
|                               | <b>Individualized Management - A clinical possibility</b><br>Chairman: <b>Keith Martin</b> (United Kingdom) |                 |
| <b>12.00</b><br><b>IS13.1</b> | Introduction by Chair<br><b>Keith Martin</b> (United Kingdom)   |                 |
| <b>12.05</b><br><b>IS13.2</b> | Risk is personal<br><b>Francisco Javier Goñi</b> (Spain)  |                 |
| <b>12.25</b><br><b>IS3.3</b>  | Every glaucoma patient is individual<br><b>David Crabb</b> (United Kingdom)                                 |                 |
| <b>12.45</b><br><b>IS13.4</b> | Redefining intervention<br><b>Ingeborg Stalmans</b> (Belgium)   |                 |
| <b>13.05</b><br><b>IS13.5</b> | Individualization in practice<br><b>Alain Bron</b> (France)   |                 |
| <b>13.25</b><br><b>IS13.6</b> | Questions & answers and wrap up<br><b>Keith Martin</b> (United Kingdom)                                     |                 |